New targeted therapy blocks metabolism in brain cancer cells with genetic vulnerability
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects. Preclinical studies found the small-molecule enolase inhibitor to be effective in killing brain cancer cells that were missing ENO1, one of two genes encoding the enolase enzyme.
The study results, published today in Nature...
MD Anderson and Obsidian Therapeutics announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration designed...
MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
ABSTRACTS 277, 368, 420
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight...
Large-scale cancer proteomics study profiles protein changes in response to drug treatments
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting drug sensitivity, to understand therapeutic resistance mechanisms and to identify optimal combination treatment strategies.
Their findings, published today in Cancer Cell, include expression changes in more...
Focus Fund and MD Anderson launch investment fund to support promising investigational cancer therapies in early-stage clinical trials
The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused...
MD Anderson and Astex Pharmaceuticals announce strategic collaboration to accelerate clinical evaluation of therapies for patients with leukemia
The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co....
MD Anderson returning to normal operations on Monday, March 2
The University of Texas MD Anderson Cancer Center is preparing to return to normal operations on Monday morning, March 2, after operating...